Citizens Maintains Market Outperform on Opus Genetics, Lowers Price Target to $11
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Citizens analyst Jonathan Wolleben maintains Opus Genetics (NASDAQ:IRD) with a Market Outperform and lowers the price target from $12 to $11.
Citizens analyst Jonathan Wolleben maintains Opus Genetics (NASDAQ:IRD) with a Market Outperform and lowers the price target from $12 to $11.